As We See It

A Tale of Two Cities

By Dan McFadden
Oculus Director of Investor Relations

As director of investor and public relations at Oculus, I have one of the best jobs in the company. Since I joined the Oculus team in January 2004, I’ve had the pleasure of meeting with hundreds of doctors/patients from around the globe (in my efforts to document through video, photos and written chronicle, their experiences) that have been successfully treated with the Microcyn Technology. It’s truly an uplifting experience when you can see the real-world impact of saving patient lives.

Posted in Patient Success Stories by Dan McFadden on July 1st, 2010
No Comments »

Success Stories from the Field

By Jim Schutz
Oculus COO

I hope this message finds you all well.

All is well at Oculus after a solid Q4 earnings call in early June. In anticipation of our earnings calls, we typically prepare several days in advance to ensure our message is clear and concise. Our message on this call was clear-cut: Revenue was up in the United States, Mexico, China, India and the Middle East with 65%+ growth and expenses were flat across the board.

Posted in Patient Success Stories by Jim Schutz on June 28th, 2010
No Comments »

What a Difference a Year Makes!

As part of my responsibilities as the CEO of Oculus, I attend various financial conferences where we present the Oculus story to investment funds or institutions. Just this week, we attended an annual growth stock conference in Southern California. We presented to a room full of investors (you can view/hear the presentation by visiting http://www.wsw.com/webcast/roth23/ocls/ ) and then followed with a series of one-on-one meetings for 30-minutes or so with individual fund managers.

Posted in Oculus Future by Hoji Alimi on March 25th, 2010
No Comments »

One Patient’s Experience: The Genesis Behind The New Microcyn HydroGel for Dermatology

Jim Schutz
Oculus Chief Operating Officer

As you may have recently read, we received a clearance from the FDA for our new Microcyn Dermatology HydroGel product, our first dermatology product and a terrific new opportunity for the team at Oculus.

We’ve been quizzed repeatedly the last several days for the “story” behind the new product and our push into dermatology. Bear with me for a peek behind the scenes.

Posted in Dermatology by Jim Schutz on March 10th, 2010
No Comments »

Keeping it in Perspective

By Hoji Alimi, Oculus Founder and CEO

I just returned from three days in San Francisco where I presented at one of the largest investor healthcare conferences of the year. The economic sentiment this year, versus last, was upbeat and optimistic. As CEO of Oculus, I was elated to share with the investment community that Oculus has reached an inflection point in our growth, with seven new FDA clearances and product introductions targeted for the United States in 2010. The investors we met with this week along with the general market response has been favorable to our news.

Posted in Global Outreach by Hoji Alimi on January 15th, 2010
1 Comment »

Microcyn® Technology vs. Antibiotics: A comparative view of Microcyn Technology products, liquids and gels, containing HOCl and topical and systemic products containing antibiotics.

Dr. Eileen Thatcher
Professor Emeritus
Sonoma State University

The antimicrobial agent in Microcyn Technology is hypochlorous acid (HOCl), is found naturally produced in animals and humans for protection against infectious agents, including bacteria, viruses, yeasts and some fungi. This small molecule is nontoxic to host cells at the concentrations used in Microcyn Technology and does not cause the development of allergic reactions with repeated use.

Posted in Antibiotics by Eileen Thatcher on January 5th, 2010
No Comments »

Increasing Shareholder Value in 2010

Hoji Alimi
Oculus Founder and CEO

If you’ve read our recent press release, you know that the Oculus R&D and marketing teams have been quite busy crafting a regulatory and product strategy for 2010 that outlines an exciting list of milestones and provides a high level of transparency. In speaking with our shareholders, both large and small, there’s been a consistent question I’ve heard: “The financial strategy to reach breakeven is an important milestone. How will you increase revenue following the breakeven so that we can see (and calculate) a ramp in earnings per share?”

Posted in New Microcyn Products by Hoji Alimi on December 14th, 2009
1 Comment »

Stories We Love to Hear

Jim Schutz
Oculus Chief Operating Officer

The team at Oculus loves to share patient stories, in the lunch room, during the long commutes fighting California’s (and Seattle’s – R&D is in Seattle) traffic and today, on our investor dialogue site, As We See It.

A terrific new patient story made the rounds this week, this one from Phoenix, Arizona.

Posted in Patient Success Stories by Jim Schutz on November 30th, 2009
No Comments »

Silver-Based Wound Care Products

Robert Northey Ph.D
Oculus Director of Research and Development

The antimicrobial properties of silver have been well known for centuries. In the ionic form Ag⁺, silver has good antimicrobial properties against a broad spectrum of gram-positive and gram-negative bacteria^1,2. It is used in the treatment of burns and wounds for the reduction of bioburden. Silver, as soluble salts, chelates, or nano crystals, is applied topically in solutions, creams, or gels. It is also incorporated as a slow release agent into a wide variety of dressing.

Posted in Silver-Based Wound Care Products by Robert Northey, Ph.D on November 24th, 2009
No Comments »

A Sunday Update Over a Strong Cup of Coffee

Jim Schutz
Oculus Chief Operating Officer

We announced our earnings for the quarter ending September 30, 2009, on Thursday and we had a good quarter. We hit our numbers on both the revenue side ($1.7M – an increase of 37% in constant currency) and expense side (cash operating expenses were $2.7M). Borrowing a line from our tissue care sales team – our financials look “pink and healthy” and in light of these trying economic times, the patient has a bright future.

Posted in Oculus Future by Jim Schutz on November 9th, 2009
No Comments »

Categories